In Women with Polycystic Ovarian Syndrome (PCOS), Oral Melatonin Supplementation Had a Modest Effect on Sleep and No Effect on Depression—Results from a Randomized Clinical Trial-Journal of Psychiatry and Brain Science-CSCIED科技核心评价数据库-手机版

In Women with Polycystic Ovarian Syndrome (PCOS), Oral Melatonin Supplementation Had a Modest Effect on Sleep and No Effect on Depression—Results from a Randomized Clinical Trial

In Women with Polycystic Ovarian Syndrome (PCOS), Oral Melatonin Supplementation Had a Modest Effect on Sleep and No Effect on Depression—Results from a Randomized Clinical Trial

ES评分 0 浏览量：166 下载量：0

全文阅读下载引用收藏

DOI	10.20900/jpbs.20250018
刊名	Journal of Psychiatry and Brain Science JPBS
年，卷(期)	2025, 10(6)
作者	Katayoun Yazdchi,Soheila Ansaripour,Sadaf Eghtedar,Zahra Heydari,Vahid Farnia,Mostafa Alikhani,Safora Salem,Annette B. Brüh,Dena Sadeghi-Bahmani,Serge Brand*,
作者单位	Reproductive Biotechnology Research Center, Avicenna Research Institute (ARI), ACECR, Tehran 1941913114, Iran ; Substance Abuse Prevention Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah 6719851151, Iran ; Center for Affective, Stress and Sleep Disorders, Psychiatric Clinics, University of Basel, Basel 4002, Switzerland ; Center for Disaster Psychiatry and Disaster Psychology, Center of Competence of Disaster Medicine of the Swiss Armed Forces, Basel 4002, Switzerland ;
摘要	Background: About 4% to 12% of women in their fertile age suffer from polycystic ovarian syndrome (PCOS). Typically, women with PCOS report higher symptoms of depression, insomnia, and stress. To improve psychophysiological PCOS-related stress and insomnia, melatonin may have favorable effects. Accordingly, the present study aimed to investigate among women with PCOS, if melatonin improved symptoms of sleep disturbances and depression, compared to a placebo condition. Methods: A total of 72 women (mean age: 31.21 years) with PCOS-related infertility were randomly assigned either to the melatonin or to the placebo condition. Melatonin/placebo intake lasted for six consecutive weeks (3 mg/d). At baseline and six weeks later at study end, participants completed a series of self-rating questionnaires on sleep patterns (Insomnia Severity Index (ISI); Pittsburgh Sleep Quality Index (PSQI); obstructive sleep apnea (OSA); restless legs syndrome (RLS)) and depression. After the study, participants underwent intracytoplasmic sperm injection (ICSI). Results: OSA- and RLS-related values did not vary over time and within and between the melatonin and placebo conditions. Over time and irrespective of the melatonin or placebo condition, scores for insomnia decreased (significant p-value and medium effect size). Over time, scores for sleep disturbances descriptively decreased in the melatonin condition and descriptively increased in the placebo condition (medium effect size for the Time by Condition interaction). Next, scores for depression decreased descriptively over time, and irrespective of the study condition (always medium effect sizes). Conclusions: The pattern of results suggests that, among women with PCOS and compared to placebo, overall, the effect of melatonin on sleep patterns and depression was modest. Future studies might focus on further standardized psychotherapeutic interventions, such as CBTi, to improve sleep and mood and to decrease PCOS-related psychosocial stress.
Abstract	Background: About 4% to 12% of women in their fertile age suffer from polycystic ovarian syndrome (PCOS). Typically, women with PCOS report higher symptoms of depression, insomnia, and stress. To improve psychophysiological PCOS-related stress and insomnia, melatonin may have favorable effects. Accordingly, the present study aimed to investigate among women with PCOS, if melatonin improved symptoms of sleep disturbances and depression, compared to a placebo condition. Methods: A total of 72 women (mean age: 31.21 years) with PCOS-related infertility were randomly assigned either to the melatonin or to the placebo condition. Melatonin/placebo intake lasted for six consecutive weeks (3 mg/d). At baseline and six weeks later at study end, participants completed a series of self-rating questionnaires on sleep patterns (Insomnia Severity Index (ISI); Pittsburgh Sleep Quality Index (PSQI); obstructive sleep apnea (OSA); restless legs syndrome (RLS)) and depression. After the study, participants underwent intracytoplasmic sperm injection (ICSI). Results: OSA- and RLS-related values did not vary over time and within and between the melatonin and placebo conditions. Over time and irrespective of the melatonin or placebo condition, scores for insomnia decreased (significant p-value and medium effect size). Over time, scores for sleep disturbances descriptively decreased in the melatonin condition and descriptively increased in the placebo condition (medium effect size for the Time by Condition interaction). Next, scores for depression decreased descriptively over time, and irrespective of the study condition (always medium effect sizes). Conclusions: The pattern of results suggests that, among women with PCOS and compared to placebo, overall, the effect of melatonin on sleep patterns and depression was modest. Future studies might focus on further standardized psychotherapeutic interventions, such as CBTi, to improve sleep and mood and to decrease PCOS-related psychosocial stress.
关键词	melatonin; polycystic ovarian syndrome; intra cytoplasmic sperm injection; sleep; depression
KeyWord	melatonin; polycystic ovarian syndrome; intra cytoplasmic sperm injection; sleep; depression
基金项目
页码	-

参考文献
相关文献

1.Salari N, Nankali A, Ghanbari A, Jafarpour S, Ghasemi H, Dokaneheifard S, et al. Global prevalence of polycystic ovary syndrome in women worldwide: A comprehensive systematic review and meta-analysis. Arch Gynecol Obstet. 2024;310(3):1303-14.

2.Escobar-Morreale HF. Polycystic ovary syndrome: Definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018;14(5):270-84.

3.Alvarez-Blasco F, Botella-Carretero JI, San Millán JL, Escobar-Morreale HF. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med. 2006;166(19):2081-6.

4.Chiaffarino F, Cipriani S, Dalmartello M, Ricci E, Esposito G, Fedele F, et al. Prevalence of polycystic ovary syndrome in European countries and USA: A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2022;279:159-70.

5.Peigné M, Villers-Capelle A, Robin G, Dewailly D. Hyperandrogénie féminine. La Presse Médicale. 2013;42(11):1487-99.

6.Costello MF, Misso ML, Balen A, Boyle J, Devoto L, Garad RM, et al. A brief update on the evidence supporting the treatment of infertility in polycystic ovary syndrome. Aust N Z J Obstet Gynaecol. 2019;59(6):867-73.

7.Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25.

8.Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023;108(10):2447-69.

9.Chang S, Dunaif A. Diagnosis of Polycystic Ovary Syndrome: Which Criteria to Use and When? Endocrinol Metab Clin North Am. 2021;50(1):11-23.

10.Azizi Kutenaei M, Hosseini Teshnizi S, Ghaemmaghami P, Eini F, Roozbeh N. The effects of myo-inositol vs. metformin on the ovarian function in the polycystic ovary syndrome: A systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2021;25(7):3105-15.

11.Baptiste CG, Battista MC, Trottier A, Baillargeon JP. Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol. 2010;122(1-3):42-52.

12.Eini F, Novin MG, Joharchi K, Hosseini A, Nazarian H, Piryaei A, et al. Intracytoplasmic oxidative stress reverses epigenetic modifications in polycystic ovary syndrome. Reprod Fertil Dev. 2017;29(12):2313-23.

13.Blay SL, Aguiar JV, Passos IC. Polycystic ovary syndrome and mental disorders: A systematic review and exploratory meta-analysis. Neuropsychiatr Dis Treat. 2016;12:2895-903.

14.Brutocao C, Zaiem F, Alsawas M, Morrow AS, Murad MH, Javed A. Psychiatric disorders in women with polycystic ovary syndrome: A systematic review and meta-analysis. Endocrine. 2018;62(2):318-25.

15.Yin X, Ji Y, Chan CLW, Chan CHY. The mental health of women with polycystic ovary syndrome: A systematic review and meta-analysis. Arch Womens Ment Health. 2021;24(1):11-27.

16.Hung JH, Hu LY, Tsai SJ, Yang AC, Huang MW, Chen PM, et al. Risk of psychiatric disorders following polycystic ovary syndrome: A nationwide population-based cohort study. PLoS ONE. 2014;9(5):e97041.

17.Dybciak P, Raczkiewicz D, Humeniuk E, Powrózek T, Gujski M, Małecka-Massalska T, et al. Depression in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. J Clin Med. 2023;12(20):6446.

18.Hong Z, Wu P, Zhuang H, Chen L, Hong S, Qin J. Prevalence of depression among women with polycystic ovary syndrome in mainland China: A systematic review and meta-analysis. BMC Psychiatry. 2024;24(1):920.

19.Infante-Cano M, García-Muñoz C, Matias-Soto J, Pineda-Escobar S, Villar-Alises O, Martinez-Calderon J. The prevalence and risk of anxiety and depression in polycystic ovary syndrome: An overview of systematic reviews with meta-analysis. Arch Womens Ment Health. 2025;28(3):475.

20.Nasiri-Amiri F, Faramarzi M, Omidvar S, Alizadeh-Navaei R. Depression and anxiety in adolescents and young women with polycystic ovary syndrome: A systematic review and meta-analysis. Int J Adolesc Med Health. 2023;35(3):233-42.

21.Cooney LG, Dokras A. Beyond fertility: Polycystic ovary syndrome and long-term health. Fertil Steril. 2018;110(5):794-809.

22.Barry JA, Kuczmierczyk AR, Hardiman PJ. Anxiety and depression in polycystic ovary syndrome: A systematic review and meta-analysis. Hum Reprod. 2011;26(9):2442-51.

23.Dokras A, Clifton S, Futterweit W, Wild R. Increased risk for abnormal depression scores in women with polycystic ovary syndrome: A systematic review and meta-analysis. Obstet Gynecol. 2011;117(1):145-52.

24.Li Y, Zhang J, Zheng X, Lu W, Guo J, Chen F, et al. Depression, anxiety and self-esteem in adolescent girls with polycystic ovary syndrome: A systematic review and meta-analysis. Front Endocrinol (Lausanne). 2024;15:1399580.

25.Wang L, Su S, Xiong T, Wang M, Ding R, Tan H, et al. Prevalence and associated risk factors for depression symptoms in adolescent girls with polycystic ovary syndrome: A hospital-based cross-sectional study. Front Public Health. 2024;12:1454415.

26.Schoretsanitis G, Gastaldon C, Kalaitzopoulos DR, Ochsenbein-Koelble N, Barbui C, Seifritz E. Polycystic ovary syndrome and postpartum depression: A systematic review and meta-analysis of observational studies. J Affect Disord. 2022;299:463-9.

27.Cooney LG, Lee I, Sammel MD, Dokras A. High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: A systematic review and meta-analysis. Hum Reprod. 2017;32(5):1075-91.

28.Veltman-Verhulst SM, Boivin J, Eijkemans MJ, Fauser BJ. Emotional distress is a common risk in women with polycystic ovary syndrome: A systematic review and meta-analysis of 28 studies. Hum Reprod Update. 2012;18(6):638-51.

29.Williams S, Fido D, Sheffield D. Polycystic Ovary Syndrome (PCOS) and Non-Suicidal Self-Injury (NSSI): A Community-Based Study. Healthcare (Basel). 2022;10(6):1118.

30.Wang C, Huang T, Song W, Zhu J, Liu Y, Chen X, et al. A meta-analysis of the relationship between polycystic ovary syndrome and sleep disturbances risk. Front Physiol. 2022;13:957112.

31.Zhang J, Ye J, Tao X, Lu W, Chen X, Liu C. Sleep disturbances, sleep quality, and cardiovascular risk factors in women with polycystic ovary syndrome: Systematic review and meta-analysis. Front Endocrinol (Lausanne). 2022;13:971604.

32.Eisenberg E, Legro RS, Diamond MP, Huang H, O'Brien LM, Smith YR, et al. Sleep Habits of Women With Infertility. J Clin Endocrinol Metab. 2021;106(11):e4414-e26.

33.Fernandez RC, Moore VM, Van Ryswyk EM, Varcoe TJ, Rodgers RJ, March WA, et al. Sleep disturbances in women with polycystic ovary syndrome: Prevalence, pathophysiology, impact and management strategies. Nat Sci Sleep. 2018;10:45-64.

34.Ibrahim S, Mehra R, Tantibhedhyangkul J, Bena J, Flyckt RL. Sleep and obstructive sleep apnea in women with infertility. Sleep Breath. 2023;27(5):1733-42.

35.Jafar NKA, Bennett CJ, Moran LJ, Mansfield DR. Beyond Counting Sheep: Exploring the Link between Polycystic Ovary Syndrome and Sleep Health. Semin Reprod Med. 2023;41(1-02):45-58.

36.Teo P, Henry BA, Moran LJ, Cowan S, Bennett C. The role of sleep in PCOS: What we know and what to consider in the future. Expert Rev Endocrinol Metab. 2022;17(4):305-18.

37.Mo L, Mansfield DR, Joham A, Cain SW, Bennett C, Blumfield M, et al. Sleep disturbances in women with and without polycystic ovary syndrome in an Australian National Cohort. Clin Endocrinol (Oxf). 2019;90(4):570-8.

38.Kahal H, Kyrou I, Tahrani AA, Randeva HS. Obstructive sleep apnoea and polycystic ovary syndrome: A comprehensive review of clinical interactions and underlying pathophysiology. Clin Endocrinol (Oxf). 2017;87(4):313-9.

39.Kahal H, Kyrou I, Uthman O, Brown A, Johnson S, Wall P, et al. The association between obstructive sleep apnea and metabolic abnormalities in women with polycystic ovary syndrome: A systematic review and meta-analysis. Sleep. 2018;41(7):zsy085.

40.Kahal H, Kyrou I, Uthman OA, Brown A, Johnson S, Wall PDH, et al. The prevalence of obstructive sleep apnoea in women with polycystic ovary syndrome: A systematic review and meta-analysis. Sleep Breath. 2020;24(1):339-50.

41.He J, Ruan X, Li J. Polycystic ovary syndrome in obstructive sleep apnea-hypopnea syndrome: An updated meta-analysis. Front Endocrinol (Lausanne). 2024;15:1418933.

42.Helvaci N, Karabulut E, Demir AU, Yildiz BO. Polycystic ovary syndrome and the risk of obstructive sleep apnea: A meta-analysis and review of the literature. Endocr Connect. 2017;6(7):437-45.

43.Paditz E. Postnatal Development of the Circadian Rhythmicity of Human Pineal Melatonin Synthesis and Secretion (Systematic Review). Children (Basel). 2024;11(10):1197.

44.Shao R, Wang Y, He C, Chen L. Melatonin and its Emerging Physiological Role in Reproduction: A Review and Update. Curr Mol Med. 2024;24(4):449-56.

45.Veiga ECA, Samama M, Ikeda F, Cavalcanti GS, Sartor A, Parames SF, et al. Melatonin improves fertilization rate in assisted reproduction: Systematic review and meta-analysis. Clinics (Sao Paulo). 2024;79:100397.

46.Hu KL, Ye X, Wang S, Zhang D. Melatonin Application in Assisted Reproductive Technology: A Systematic Review and Meta-Analysis of Randomized Trials. Front Endocrinol (Lausanne). 2020;11:160.

47.Mejlhede MAB, Jepsen JB, Knudsen UB. Oral melatonin supplementation during in vitro fertilization treatment: A systematic PRISMA review and meta-analysis of randomized controlled trials. Gynecol Endocrinol. 2021;37(12):1079-85.

48.Showell MG, Mackenzie-Proctor R, Jordan V, Hart RJ. Antioxidants for female subfertility. Cochrane Database Syst Rev. 2020;8(8):Cd007807.

49.Azim SS, Haque Z, Khan S, Hasan JA, Zaheer S, Parveen S. Oxidative stress in polycystic ovary syndrome: A case-control study. J Pak Med Assoc. 2024;74(1 (Supple-2)):S2-S7.

50.Kobayashi H, Matsubara S, Yoshimoto C, Shigetomi H, Imanaka S. A Comprehensive Review of the Contribution of Mitochondrial DNA Mutations and Dysfunction in Polycystic Ovary Syndrome, Supported by Secondary Database Analysis. Int J Mol Sci. 2025;26(3):1172.

51.Olcese JM. Melatonin and Female Reproduction: An Expanding Universe. Front Endocrinol (Lausanne). 2020;11:85.

52.Shang Y, Song N, He R, Wu M. Antioxidants and Fertility in Women with Ovarian Aging: A Systematic Review and Meta-Analysis. Adv Nutr. 2024;15(8):100273.

53.Dehdari Ebrahimi N, Sadeghi A, Ala M, Ebrahimi F, Pakbaz S, Azarpira N. Protective effects of melatonin against oxidative stress induced by metabolic disorders in the male reproductive system: A systematic review and meta-analysis of rodent models. Front Endocrinol (Lausanne). 2023;14:1202560.

54.Dehdari Ebrahimi N, Sadeghi A, Shojaei-Zarghani S, Shahlaee MA, Taherifard E, Rahimian Z, et al. Protective effects of exogenous melatonin therapy against oxidative stress to male reproductive tissue caused by anti-cancer chemical and radiation therapy: A systematic review and meta-analysis of animal studies. Front Endocrinol (Lausanne). 2023;14:1184745.

55.Ghorbaninejad P, Sheikhhossein F, Djafari F, Tijani AJ, Mohammadpour S, Shab-Bidar S. Effects of melatonin supplementation on oxidative stress: A systematic review and meta-analysis of randomized controlled trials. Horm Mol Biol Clin Investig. 2020;41(4):20200030.

56.Zarezadeh M, Barzegari M, Aghapour B, Adeli S, Khademi F, Musazadeh V, et al. Melatonin effectiveness in amelioration of oxidative stress and strengthening of antioxidant defense system: Findings from a systematic review and dose-response meta-analysis of controlled clinical trials. Clin Nutr ESPEN. 2022;48:109-20.

57.Zarezadeh M, Khorshidi M, Emami M, Janmohammadi P, Kord-Varkaneh H, Mousavi SM, et al. Melatonin supplementation and pro-inflammatory mediators: A systematic review and meta-analysis of clinical trials. Eur J Nutr. 2020;59(5):1803-13.

58.Li Y, Xu Z. Effects of Melatonin Supplementation on Insulin Levels and Insulin Resistance: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Horm Metab Res. 2021;53(9):616-24.

59.Auld F, Maschauer EL, Morrison I, Skene DJ, Riha RL. Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders. Sleep Med Rev. 2017;34:10-22.

60.Choi K, Lee YJ, Park S, Je NK, Suh HS. Efficacy of melatonin for chronic insomnia: Systematic reviews and meta-analyses. Sleep Med Rev. 2022;66:101692.

61.Fatemeh G, Sajjad M, Niloufar R, Neda S, Leila S, Khadijeh M. Effect of melatonin supplementation on sleep quality: A systematic review and meta-analysis of randomized controlled trials. J Neurol. 2022;269(1):205-16.

62.Tsukinaga A, Mihara T, Takeshima T, Tomita M, Goto T. Effects of melatonin on postoperative sleep quality: A systematic review, meta-analysis, and trial sequential analysis. Can J Anaesth. 2023;70(5):901-14.

63.Cruz-Sanabria F, Bruno S, Crippa A, Frumento P, Scarselli M, Skene DJ, et al. Optimizing the Time and Dose of Melatonin as a Sleep-Promoting Drug: A Systematic Review of Randomized Controlled Trials and Dose-Response Meta-Analysis. J Pineal Res. 2024;76(5):e12985.

64.Maruani J, Reynaud E, Chambe J, Palagini L, Bourgin P, Geoffroy PA. Efficacy of melatonin and ramelteon for the acute and long-term management of insomnia disorder in adults: A systematic review and meta-analysis. J Sleep Res. 2023;32(6):e13939.

65.Hansen MV, Danielsen AK, Hageman I, Rosenberg J, Gögenur I. The therapeutic or prophylactic effect of exogenous melatonin against depression and depressive symptoms: A systematic review and meta-analysis. Eur Neuropsychopharmacol. 2014;24(11):1719-28.

66.Li C, Ma D, Li M, Wei T, Zhao X, Heng Y, et al. The Therapeutic Effect of Exogenous Melatonin on Depressive Symptoms: A Systematic Review and Meta-Analysis. Front Psychiatry. 2022;13:737972.

67.De Crescenzo F, Lennox A, Gibson JC, Cordey JH, Stockton S, Cowen PJ, et al. Melatonin as a treatment for mood disorders: A systematic review. Acta Psychiatr Scand. 2017;136(6):549-58.

68.Demirhan Kayacik A, İlcioglu K. Effects of melatonin intake on depression and anxiety in postmenopausal women: A systematic review and meta-analysis of randomised controlled trials. Arch Womens Ment Health. 2024;27(2):265-73.

69.Shokri-Mashhadi N, Darand M, Rouhani MH, Yahay M, Feltham BA, Saraf-Bank S. Effects of melatonin supplementation on BDNF concentrations and depression: A systematic review and meta-analysis of randomized controlled trials. Behav Brain Res. 2023;436:114083.

70.Baradwan S, Gari A, Sabban H, Alshahrani MS, Khadawardi K, Bukhari IA, et al. The effect of antioxidant supplementation on dysmenorrhea and endometriosis-associated painful symptoms: A systematic review and meta-analysis of randomized clinical trials. Obstet Gynecol Sci. 2024;67(2):186-98.

71.Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175-91.

72.Mokhtari F, Akbari Asbagh F, Azmoodeh O, Bakhtiyari M, Almasi-Hashiani A. Effects of Melatonin Administration on Chemical Pregnancy Rates of Polycystic Ovary Syndrome Patients Undergoing Intrauterine Insemination: A Randomized Clinical Trial. Int J Fertil Steril. 2019;13(3):225-9.

73.Chehri A, Brand S, Goldaste N, Eskandari S, Brühl A, Sadeghi Bahmani D, et al. Psychometric Properties of the Persian Pittsburgh Sleep Quality Index for Adolescents. Int J Environ Res Public Health. 2020;17(19):7095.

74.Farrahi Moghaddam J, Nakhaee N, Sheibani V, Garrusi B, Amirkafi A. Reliability and validity of the Persian version of the Pittsburgh Sleep Quality Index (PSQI-P). Sleep & Breath = Schlaf & Atm. 2012;16(1):79-82.

75.Buysse DJ, Reynolds CF, 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193-213.

76.Sadeghniiat-Haghighi K, Montazeri A, Khajeh-Mehrizi A, Nedjat S, Aminian O. The Insomnia Severity Index: Cross-cultural adaptation and psychometric evaluation of a Persian version. Qual Life Res: Int J Qual Life Asp Treat Care & Rehabil. 2014;23(2):533-7.

77.Yazdi Z, Sadeghniiat-Haghighi K, Zohal MA, Elmizadeh K. Validity and reliability of the Iranian version of the insomnia severity index. Malays J Med Sci: MJMS. 2012;19(4):31-6.

78.Bastien CH, Vallieres A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001;2(4):297-307.

79.American Psychiatric Association. Diagnostic and Statistical manual of Mental Disorders 4th edition: DSM-IV-TR. Washington (DC, US): American Psychiatric Association; 2000.

80.Sadeghniiat-Haghighi K, Montazeri A, Khajeh-Mehrizi A, Ghajarzadeh M, Alemohammad ZB, Aminian O, et al. The STOP-BANG questionnaire: Reliability and validity of the Persian version in sleep clinic population. Qual Life Res. 2015;24(8):2025-30.

81.Larner A, Ziso B. Screening for obstructive sleep apnoea using the STOPBANG questionnaire. Clin Med (Lond). 2018;18(1):108-9.

82.Chung F, Yegneswaran B, Liao P, Chung SA, Vairavanathan S, Islam S, et al. STOP questionnaire: A tool to screen patients for obstructive sleep apnea. Anesthesiology. 2008;108(5):812-21.

83.Modarresnia L, Golgiri F, Madani NH, Emami Z, Tanha K. Restless Legs Syndrome in Iranian People With Type 2 Diabetes Mellitus: The Role in Quality of Life and Quality of Sleep. J Clin Sleep Med. 2018;14(2):223-8.

84.Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisi J. Restless legs syndrome: Diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003;4(2):101-19.

85.Sadeghi Bahmani D, Razazian N, Motl RW, Farnia V, Alikhani M, Pühse U, et al. Physical activity interventions can improve emotion regulation and dimensions of empathy in persons with multiple sclerosis: An exploratory study. Mult Scler Relat Disord. 2020;37:101380.

86.Benedict RH, Fishman I, McClellan MM, Bakshi R, Weinstock-Guttman B. Validity of the Beck Depression Inventory-Fast Screen in multiple sclerosis. Mult Scler. 2003;9(4):393-6.

87.Lu Q, Cheng Y, Zhou Z, Fan J, Chen J, Yan C, et al. Effects of emotions on IVF/ICSI outcomes in infertile women: A systematic review and meta-analysis. J Assist Reprod Genet. 2025;42(4):1083-99.

88.Peng M, Wen M, Jiang T, Jiang Y, Lv H, Chen T, et al. Stress, anxiety, and depression in infertile couples are not associated with a first IVF or ICSI treatment outcome. BMC Pregnancy Childbirth. 2021;21(1):725.

89.Darwiche J, Lawrence C, Vial Y, Wunder D, Stiefel F, Germond M, et al. Anxiety and psychological stress before prenatal screening in first-time mothers who conceived through IVF/ICSI or spontaneously. Women Health. 2014;54(5):474-85.

90.Paraskevi L, Antigoni S, Kleanthi G. Stress and Anxiety Levels in Couples who Undergo Fertility Treatment: A Review of Systematic Reviews. Mater Sociomed. 2021;33(1):60-4.

91.Zhu Y, Stephenson C, Moghimi E, Jagayat J, Nikjoo N, Kumar A, et al. Investigating the effectiveness of electronically delivered cognitive behavioural therapy (e-CBTi) compared to pharmaceutical interventions in treating insomnia: Protocol for a randomized controlled trial. PLoS ONE. 2023;18(5):e0285757.

92.de Bruin EJ, Bogels SM, Oort FJ, Meijer AM. Efficacy of Cognitive Behavioral Therapy for Insomnia in Adolescents: A Randomized Controlled Trial with Internet Therapy, Group Therapy and A Waiting List Condition. Sleep. 2015;38(12):1913-26.

93.Reynolds AC, Sweetman A, Crowther ME, Paterson JL, Scott H, Lechat B, et al. Is cognitive behavioral therapy for insomnia (CBTi) efficacious for treating insomnia symptoms in shift workers? A systematic review and meta-analysis. Sleep Med Rev. 2023;67:101716.

94.Sweetman A, Farrell S, Wallace DM, Crawford M. The effect of cognitive behavioural therapy for insomnia in people with comorbid insomnia and sleep apnoea: A systematic review and meta-analysis. J Sleep Res. 2023;32(6):e13847.

95.Khazaie H, Zakiei A. Efficacy of Acceptance and Commitment Therapyon Emotional Dysregulation and Sleep Quality in Patientswith Chronic Insomnia. J Mazandaran Univ Med Sci. 2019;29(178):52-63.

96.Zakiei A, Khazaie H, Rostampour M, Lemola S, Esmaeili M, Dürsteler K, et al. Acceptance and Commitment Therapy (ACT) Improves Sleep Quality, Experiential Avoidance, and Emotion Regulation in Individuals with Insomnia-Results from a Randomized Interventional Study. Life (Basel). 2021;11(2):133.

97.World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-4

引用本文

Katayoun Yazdchi,Soheila Ansaripour,Sadaf Eghtedar,Zahra Heydari,Vahid Farnia,Mostafa Alikhani,Safora Salem,Annette B. Brüh,Dena Sadeghi-Bahmani,Serge Brand*. In Women with Polycystic Ovarian Syndrome (PCOS), Oral Melatonin Supplementation Had a Modest Effect on Sleep and No Effect on Depression—Results from a Randomized Clinical Trial [J]. Journal of Psychiatry and Brain Science. 2025; 10; (6). - .

文献评论

相关学者

相关机构